Ginkgo biloba effects in the treatment of patients with chronic schizophrenia treated with Risperidone in Joneghan Sinai Hospital

Not Applicable

• Conditions: Schizophrenia.; Schizophrenia; F20, F29

• Registration Number: IRCT138903192085N3
• Lead Sponsor: Shahrekord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Schizophrenia diagnosis
Exclusion criteria: Use of other herbal medicines, aspirin or anticoagulant drugs, clotting problems before and during treatment with Ginkgo

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improve positive and negative signs. Timepoint: at the begining, 2, 4, 6, 8, 12 weeks after treatment and one month after end of treatment. Method of measurement: complete Anderson positive and negative questionnaire.